chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Within 5 or 6 minutes after receiving the vaccine, the left arm began feeling sore and the left wrist slightly achey. The arm got progressively more sore over the next 18-24 hours. A penny-sized bruise appeared at the site of injection about 18 hours post-injection. No medication was taken for the arm soreness or  bruising. Excessive tiredness also occurred about 20-22 hours post-injection, resulting in a heavy sleep for two hours mid-day on 13 April 2021 but patient continued to feel tired. On 14 April 2021, patient awoke with swollen lymph glands in the neck area and tenderness in the back of the throat when she swallowed. At about 34-36 hours post injection, the patient again experienced excessive tiredness and new adverse events of mild headache, muscle aches throughout the body, and aches in the ankle and hip joints. At this point, patient took two tablets of 200-mg ibuprofen along with water, coconut water, and hot tea to stay hydrated. At this point, patient reported these adverse events but has not yet recovered.
extreme chills, fatigue, total loss of appetite with weight loss, getting winded - aka shortness of breath all for 5-7 days, extreme muscle pain at injection site for 3 days.
Numbness in fingers and feet loss of ability to walk headache jaw lock pain in back and legs and arms.
Overly tired, shortness of breath, chest pain, leg pain After 3wks of symptoms patient(self) went to hospital and it has been discovered patient has ( self) has a blood clot in Right lung. Patient (self) has no record or history of blood clots. Was treated with heparin while in hospital. Has since been discharged and sent home with a prescription for anticoagulant.
COVID vaccine has countered Pneumonia vaccine; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A patient (no qualifiers provided) received BNT162b2 (BNT162B2 NOS), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation; methylprednisolone sodium succinate (SOLU-MEDROL); atropine sulfate (ATROPINE SULFATE); pneumococcal vaccine (PNEUMOCOCCAL VACCINE), as dose number unknoiwn, single (Batch/Lot number: unknown) for immunisation; fluticasone propionate, salmeterol xinafoate (WIXELA INHUB), (Batch/Lot number: unknown); albuterol [salbutamol] (ALBUTEROL [SALBUTAMOL]), (Batch/Lot number: unknown); ipratropium (IPRATROPIUM), (Batch/Lot number: unknown); pantoprazole (DUPAN), (Batch/Lot number: unknown). The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INTERACTION (non-serious), outcome "unknown", described as "COVID vaccine has countered Pneumonia vaccine". The action taken for methylprednisolone sodium succinate, atropine sulfate, fluticasone propionate, salmeterol xinafoate, albuterol [salbutamol], ipratropium and pantoprazole was unknown. Additional information: COVID vaccine has countered Pneumonia vaccine. The Pfizer drug (Unspecified medication) interacted with Wixela.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Major reaction/little bit of a reaction but now it was really bad/looked deformed; Everything seems amplified; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Major reaction/little bit of a reaction but now it was really bad/looked deformed) and FEELING ABNORMAL (Everything seems amplified) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 088P/D21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included ABATACEPT (ORENCIA), BUDESONIDE, FORMOTEROL FUMARATE (SYMBICORT), SALBUTAMOL SULFATE (PROAIR [SALBUTAMOL SULFATE]), THYROID (ARMOUR THYROID), DULOXETINE HYDROCHLORIDE (CYMBALTA) and VITAMINS NOS for an unknown indication.    On 06-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Aug-2021, the patient experienced VACCINATION COMPLICATION (Major reaction/little bit of a reaction but now it was really bad/looked deformed) and FEELING ABNORMAL (Everything seems amplified). At the time of the report, VACCINATION COMPLICATION (Major reaction/little bit of a reaction but now it was really bad/looked deformed) and FEELING ABNORMAL (Everything seems amplified) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       On 09-Aug-2021,Patient received Botox and Guvederm treatment after first dose. Patient had this kind of treatment for 4 years and normally had little bit of reaction.  No treatment information was provided.   This case was linked to MOD-2021-333709 (Patient Link).
pt recv vax 1130AM APAP given & devel temp 103.9, trembling, lifeless, t105 instructed to call PMD when pt reached office;APAP alternated w/advil;adviced no more pertussis;
Patient presented to the ED and was subsequently hospitalized for Atrial flutter with rapid ventricular response within 6 weeks of receiving covid vaccination.
Reddened 9cm x 7cm somewhat swollen area to left upper arm. Treated with Duricef 250/5 tsp BID for 10 days and Benadryl PRN.
overall weakness; lack of appetite; moderate dehydration; injection site was sore; injection site was red; moderate perspiration; fainting symptoms; increase in nausea; dizziness; greater level of fatigue; severe chills; body aches were severe; A spontaneous report was received from a consumer concerning a 54-years-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced greater level of fatigue, increasing to prominent weakness, severe chills, body aches, dizziness, nausea, fainting symptoms, moderate perspiration, weakness, moderate dehydration, lack of appetite, injection site sore and red.  The patient's medical history includes severe asthma. Concomitant medications reported were Budesonide / Formoterol for drug use for unknown indication.  On 15 Jan 2021, prior to the onset of the events the patient received her first of two planned doses of mRNA-1273 (lot/batch: 041L20A) intramuscularly in the left arm for prophylaxis of COVID-19 infection. On 12 Feb 2021, prior to the onset of the events the patient received their second of two planned doses of mRNA-1273 (lot/batch: 062620A) intramuscularly in the left arm for prophylaxis of COVID-19 infection.  On 12 Feb 2021, the patient experienced greater level of fatigue, increasing to prominent weakness, severe chills, fluctuation in her body temperature it alternated from cold to heat, body aches were severe. On 13/Feb/2021, the patient experienced the event(s) dizziness. increase in nausea, fainting symptoms, moderate perspiration. On 14 Feb 2021, the patient experienced  overall weakness. moderate dehydration, lack of appetite, injection site was sore and red. It all lasted 2-3 days  Treatment details were not provided.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of events,  fatigue, weakness, severe chills, body aches, dizziness, nausea, fainting symptoms, moderate perspiration, overall weakness, moderate dehydration, lack of appetite, injection site sore and red, was recovered on an unknown date.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Information has been received from a nurse referring to an unknown gender patient of unknown age. Information about concomitant medications, pertinent medical history and drug reactions/allergies was not reported. On 27-FEB-2019, the patient was inadvertently vaccinated with PROQUAD (lot # reported as R026350, expiration date: 15-MAR-2020, dose, frequency and route were not reported) and VARIVAX (lot #: R026548, expiration date: 17-SEP-2020, dose, frequency and route were not reported) for prophylaxis. Concomitant therapies included sterile diluent. No adverse effect reported.
Patient had a rash around injection site, some swelling, and tenderness approximately 2 by 3 inches when viewed on 12/1/17. Advised to monitor, and that this is a possible side effect from vaccine, advised could take Benadryl  and to continue to monitor for the next 7 to days 10 days. Advised patient to follow up with her primary care physician if the rash or symptoms worsened.
Breakthrough case admission after 2 vaccines Moderna 3/6/21 Lot# 029A21A;  Moderna 4/3/21 Lot# 028A21A
ADMINISTERED PAST THE CURRENT REFIGERATION BEYOND THE USE DATE AS LISTED IN EUA
Expired vaccine used; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) in a 70-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Oct-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). On 13-Oct-2021, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  Treatment information was not provided.
Painful, swollen, itchy, red, rashes entire upper left arm from shoulder to midway to elbow, chills and fatigue. Increasing significantly on day 7 and continuing  presently.
heart problems after getting the vaccine; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A patient (no qualifiers provided) received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: CARDIAC DISORDER (non-serious), outcome "unknown", described as "heart problems after getting the vaccine".  Additional information: Event Awareness Date: 09Oct2022.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Severe allergic reaction. Child complained of mouth hurting. Then, the right top lip and the right side of the face swell up. Around 7-8pm. Doctor was called, then child was rushed to the hospital.
Around 10 pm March 4th, experienced nausea 3 am March 5th, vomited 1st time Vomited 4 other times throughout next 24 hours, with continuous nausea Also experienced diarrhea Nausea somewhat handled with a Wal-Dram (generic of Dramamine) Diarrhea addressed with Immodium Unable to eat for the first 24 hours after symptoms, only able to eat very small amounts for the following 24 After 72 hours most symptoms abated
Pt vaccinated with DTP one of two pt who developed urticaria 20 hrs after immunization.
Swelling, redness and warmth of skin surrounding site of injection (right deltoid).  Initially began as a firm lump Day 1, then spread outward from site of injection to include warmth, redness and firmness Day 2.  At time of reporting, surrounding redness, firmness of skin measures 10cm x 12cm (elliptical shape).  Also noted onset of discomfort (Day 1), then subsequent swelling and pain of right knee (Day 2).  No warmth or redness here.  Inability to bend knee back further than 90 degrees without significant pain Day 2.  Symptom onset and progression followed same course as the local reaction at site of vaccine administration.
No Adverse event; 12 year old siblings who received the Moderna's Bivalent booster instead of the Pfizer's Bivalent booster; 12 year old siblings who received the Moderna's Bivalent booster instead of the Pfizer's Bivalent booster; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (12 year old siblings who received the Moderna's Bivalent booster instead of the Pfizer's Bivalent booster), WRONG PRODUCT ADMINISTERED (12 year old siblings who received the Moderna's Bivalent booster instead of the Pfizer's Bivalent booster) and NO ADVERSE EVENT (No Adverse event) in a 12-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7146B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 17-Sep-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 17-Sep-2022, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (12 year old siblings who received the Moderna's Bivalent booster instead of the Pfizer's Bivalent booster) and WRONG PRODUCT ADMINISTERED (12 year old siblings who received the Moderna's Bivalent booster instead of the Pfizer's Bivalent booster). On an unknown date, the patient experienced NO ADVERSE EVENT (No Adverse event). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (12 year old siblings who received the Moderna's Bivalent booster instead of the Pfizer's Bivalent booster), WRONG PRODUCT ADMINISTERED (12 year old siblings who received the Moderna's Bivalent booster instead of the Pfizer's Bivalent booster) and NO ADVERSE EVENT (No Adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse event) to be not related. No further causality assessments were provided for PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (12 year old siblings who received the Moderna's Bivalent booster instead of the Pfizer's Bivalent booster) and WRONG PRODUCT ADMINISTERED (12 year old siblings who received the Moderna's Bivalent booster instead of the Pfizer's Bivalent booster).    Concomitant medication was not provided.  The dose administered was booster.  Treatment information was not provided.
Pt recv vax on 5/19/98; on 5/26/98 pt exp vax site pain
Patient complains of pain and about a 2inch hematoma noted to the left deltoid at injection site. Slightly warm to touch. Denies any fever. Advised to use warm/cold compresses. Patient stated that she has taken Ibuprofen and it has helped with pain.
Information has been received from a health professional concerning a 34 year old female who was vaccinated with a first dose of varicella virus vaccine live (Oka/Merck). Subsequently the patient experienced itching and a raised area at the injection site. The raised area lasted 3 days and the patient has recovered. It was also reported that the patient was vaccinated with a second dose of varicella virus vaccine live (Oka/Merck) intramuscularly. No product quality complaint was involved. No other information was provided. Additional information has been requested.
Tiredness and nausea for about 24 hours; Tiredness and nausea for about 24 hours; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the right arm on 07Apr2021 at 15:00 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Medical history included depression and acid reflux (esophageal). The patient previously used adhesive tape (reported as adhesive bandages) and experienced adhesive tape (reported as adhesive bandages) allergy. Concomitant medications taken within two weeks of vaccination included naproxen sodium (ALEVE) and sertraline hydrochloride (ZOLOFT); both from unknown date for unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Apr2021 at 08:00, the patient experienced tiredness and nausea for about 24 hours. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events tiredness and nausea for about 24 hours was resolved on 09Apr2021.   No follow-up attempts are needed. No further information is expected.
On 01/15/2021 I experienced spotting and started my period 2 weeks before planned. This lasted till 01/18/2021.
Pt came in. said she had no  reaction  until 1 week after her first shot, but wanted to get her second shot. She said she had swelling under arm, but said positive it was not lymph nodes, and some tightness around chin  for very short time,  and nausea for 1 month.  She said sister had same rxn but on 2nd shot had no rxn whatever, so wanted to get it. We discussed it, and I told her at least make sure you have benadryl and someone around you at all times since it was so much later rxn time if at all, than the shot, not sure if it even came from the shot except possibly the swelling under arm.  She said she understood.  5 minutes after getting the shot, during her 15 minute waiting period, she said she felt tightening in her larynx and was having trouble breathing. Gave her 50mg benadryl and called 911. While waiting for rescue squad, she said she was feeling dizzy, but she was also getting more agitated and breathing fast and deep. I told her to slow down, breath slowly and calmly. When rescue squad arrived they took over. Talked to her but she got more agitated again and they started oxygen, but only used it for about 5 minutes. They took it off, she was conscious the entire time, and they told her they wanted to transport her to ER for observation only. She stood up and got onto the gurney herself.  Tried to call her at 6pm but no answer.
Exceeded the 30 day refrigeration limit; Received Expired Dose of Vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received Expired Dose of Vaccine) and PRODUCT STORAGE ERROR (Exceeded the 30 day refrigeration limit) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 25-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-May-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received Expired Dose of Vaccine). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Exceeded the 30 day refrigeration limit). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Received Expired Dose of Vaccine) and PRODUCT STORAGE ERROR (Exceeded the 30 day refrigeration limit) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Action taken with mRNA-1273 in response to the events was not applicable.  No concomitant product use was provided by the reporter.  No treatment medication was provided.  The vials were placed in the refrigerator on 21-Apr2-021 and stayed in the same location until their administration date on 25-May-2021.
Shingles; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a currently 76 year old female patient. No information was provided regarding medical history, concurrent conditions, or concomitant medications.   On or around 23-AUG-2012, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) (lot#, expiration date, dose, dose# and route not specified) for the long-term prevention of shingles and zoster-related conditions.   On an unspecified date, the patient experienced shingles. On an unspecified date, the patient was treated by a physician for the shingles.  The outcome of the event of shingles was not reported. The reporter considered the event to be related to zoster vaccine live (ZOSTAVAX).   Additional information has been requested.
serum sickness like rxn p/4th dose in series from occupational exposure to child w/clinical rabies prior to isolation;p/5th dose lt facial numbness that started on lateral tongue & upper rt extremity numbness that is not debilitating;
Feverish on 6th and 7th day after 2nd Vaccination,and right side of neck is tender
By the next day the patient had a 5" red, hot mark at the injection site. The mark moved down his arm to his elbow. He also had a stomach ache. He applied BENADRYL cream. The symptoms were gone in 3-4 days.
Infant taken to ER by ENS for seizure activity at home.  Exam, labs and CT of head were done by doctor in the ER.  Infant followed up with doctor and he referred infant to neurologist
Since receiving  2nd shot have had stomach upset and diarrhea every day.  No loss appetite.  I had headache day of both injections which subsided by end next day and I assume regular muscle soreness but this has been ongoing since the injection.  No lower GI problems prior shot.  This is day 13 and every day.  No change in diet other than trying eat not rich foods soups and nothing helps.
pt recv vax 17SEP96 & 12hr p/vax pt exp a fever of 103 or 104;
Continuous headache; Tingle right cheek to mouth; Right hand tremor; Brain fog; Intermittent blurred vision; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 42 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 09Aug2021 18:00 (Lot number: Fc3181) at the age of 42 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Ulcerative colitis" (unspecified if ongoing); "seasonal allergies" (unspecified if ongoing); "latex Allergy" (unspecified if ongoing); "Known allergies: ct contrast on opaque" (unspecified if ongoing); "Known allergies: soy" (unspecified if ongoing); "Covid" (unspecified if ongoing). Concomitant medication(s) included: LIALDA; ZYRTEC [CETIRIZINE HYDROCHLORIDE]; FLONASE [MOMETASONE FUROATE]; PROBIOTICS. Past drug history included: Keflex, reaction(s): "Known Allergies: Keflex"; Zithromax, reaction(s): "Known Allergies: Zithromax"; Doxycycline, reaction(s): "Known Allergies: doxycycline"; Bactrim, reaction(s): "Known Allergies: Bactrim"; Levaquin, reaction(s): "Known Allergies: levaquin"; Betadine, reaction(s): "Known Allergies: betadine". The following information was reported: HEADACHE (non-serious) with onset 10Aug2021 06:00, outcome "not recovered", described as "Continuous headache"; PARAESTHESIA (non-serious) with onset 10Aug2021 06:00, outcome "not recovered", described as "Tingle right cheek to mouth"; TREMOR (non-serious) with onset 10Aug2021 06:00, outcome "not recovered", described as "Right hand tremor"; FEELING ABNORMAL (non-serious) with onset 10Aug2021 06:00, outcome "not recovered", described as "Brain fog"; VISION BLURRED (non-serious) with onset 10Aug2021 06:00, outcome "not recovered", described as "Intermittent blurred vision". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of headache, paraesthesia, tremor, feeling abnormal, vision blurred.  Additional information: Patient was not diagnosed with COVID prior to vaccination and not tested with COVID post vaccination.  Follow-up attempts are completed. No further information is expected.
Pt went to ER due to shortness of breath one day after vaccine on 2-19-21. Pt was diagnosed with pneumonia and was given antibiotics. stated the antibiotics gave the patient leg pain and then had to get pain medications.